Anticancer therapy targeting the apoptotic pathway (Q35603092)

9 August 2017

1 reference

title

Anticancer therapy targeting the apoptotic pathway (English)

1 reference

9 August 2017

0 references

Wei Hu

1

1 reference

9 August 2017

John J Kavanagh

series ordinal

2

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Lancet Oncology Commission

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

721-729

1 reference

Programmed cell death: many ways for cells to die decently.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Apoptosis-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The IAP family: endogenous caspase inhibitors with multiple biological activities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Alternative splicing variants of c-FLIP transduce the differential signal through the Raf or TRAF2 in TNF-induced cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The CD95(APO-1/Fas) DISC and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Signaling and transcriptional control of Fas ligand gene expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Apo2L/TRAIL and its death and decoy receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

On the TRAIL to apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The Bcl-2 protein family: arbiters of cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The biochemistry of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

BCL-2 family members and the mitochondria in apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Apoptosis and melanoma: molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

A high easy-to-treat complication rate is the price for continent stoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Dueling activities of AIF in cell death versus survival: DNA binding and redox activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

XIAP: apoptotic brake and promising therapeutic target.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Control of apoptosis and mitotic spindle checkpoint by survivin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The role of survivin as a new target of diagnosis and treatment in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

New insights into the role of nuclear factor-kB in cell growth regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Heat shock proteins in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Heat shock proteins--modulators of apoptosis in tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The chaperone function of hsp70 is required for protection against stress-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Negative regulation of the Apaf-1 apoptosome by Hsp70

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

BAG-1 modulates the chaperone activity of Hsp70/Hsc70.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Heat-shock protein 70 antagonizes apoptosis-inducing factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Apoptosis regulating proteins as targets of therapy for haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

TRAIL/Apo-2L: mechanisms and clinical applications in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Death receptor ligands, in particular TRAIL, to overcome drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Inhibition of bcl-2 as cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Cellular response to a glutathione S-transferase P1-1 activated prodrug.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Activity of TER286 against human tumor colony-forming units

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Signal transduction by the JNK group of MAP kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The ups and downs of MEK kinase interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Development of the proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

High-dose therapy and immunomodulatory drugs in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Proteasome inhibition: a novel approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Proteasome inhibition in cancer: development of PS-341.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

The proteasome: a new target for novel drug therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Proteasome inhibition: a new strategy in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Histone deacetylases as therapeutic targets in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Local delivery for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Farnesyl transferase inhibitors in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901277-4

7 January 2021

10.1016/S1470-2045(03)01277-4

Identifiers

DOI

1 reference

9 August 2017

1 reference